Patrick M. O'Connor, Ph.D., Selexagen Therapeutics

Caption: Patrick M. O'Connor, Ph.D., is chief scientific officer of Selexagen Therapeutics and editorial board member for Cancer Research.

Credit: Patrick M. O'Connor, Ph.D.

Usage Restrictions: None

Related news release: Double-therapy approach effectively inhibited brain cancer recurrence